[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60228945D1 - Verwendung von cd25-bindender moleküle für patienten mit steroide-resistenz - Google Patents

Verwendung von cd25-bindender moleküle für patienten mit steroide-resistenz

Info

Publication number
DE60228945D1
DE60228945D1 DE60228945T DE60228945T DE60228945D1 DE 60228945 D1 DE60228945 D1 DE 60228945D1 DE 60228945 T DE60228945 T DE 60228945T DE 60228945 T DE60228945 T DE 60228945T DE 60228945 D1 DE60228945 D1 DE 60228945D1
Authority
DE
Germany
Prior art keywords
patients
binding molecules
steroid
steroid resistance
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60228945T
Other languages
English (en)
Inventor
Stephen David Hearing
Colin Mark Dayan
Michael Roden Norman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27256143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60228945(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0108821A external-priority patent/GB0108821D0/en
Priority claimed from GB0108817A external-priority patent/GB0108817D0/en
Priority claimed from GB0108816A external-priority patent/GB0108816D0/en
Application filed by University of Bristol filed Critical University of Bristol
Application granted granted Critical
Publication of DE60228945D1 publication Critical patent/DE60228945D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
DE60228945T 2001-04-06 2002-04-05 Verwendung von cd25-bindender moleküle für patienten mit steroide-resistenz Expired - Lifetime DE60228945D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0108821A GB0108821D0 (en) 2001-04-06 2001-04-06 Therapy
GB0108817A GB0108817D0 (en) 2001-04-06 2001-04-06 Therapy
GB0108816A GB0108816D0 (en) 2001-04-06 2001-04-06 Therapy
PCT/EP2002/003808 WO2002081508A2 (en) 2001-04-06 2002-04-05 Use of cd25 binding molecules in steroid-resistant patients

Publications (1)

Publication Number Publication Date
DE60228945D1 true DE60228945D1 (de) 2008-10-30

Family

ID=27256143

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228945T Expired - Lifetime DE60228945D1 (de) 2001-04-06 2002-04-05 Verwendung von cd25-bindender moleküle für patienten mit steroide-resistenz

Country Status (21)

Country Link
US (2) US20040146508A1 (de)
EP (2) EP2058332A1 (de)
JP (2) JP2005502593A (de)
KR (2) KR100975042B1 (de)
CN (1) CN1296386C (de)
AT (1) ATE408629T1 (de)
AU (1) AU2002315271B2 (de)
BR (1) BR0208656A (de)
CA (1) CA2443405A1 (de)
CZ (1) CZ20032672A3 (de)
DE (1) DE60228945D1 (de)
ES (1) ES2314067T3 (de)
HU (1) HUP0400986A3 (de)
IL (2) IL158060A0 (de)
MX (1) MXPA03009115A (de)
NO (1) NO20034453L (de)
NZ (1) NZ528411A (de)
PL (1) PL363029A1 (de)
PT (1) PT1379557E (de)
SK (1) SK12212003A3 (de)
WO (1) WO2002081508A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535636A (ja) * 2002-06-28 2005-11-24 アメリカ合衆国 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
CA2538737A1 (en) * 2003-09-23 2005-04-07 Pdl Biopharma, Inc. Treatment of respiratory diseases with anti-il-2 receptor antibodies
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
JP5122454B2 (ja) * 2005-08-02 2013-01-16 センテナリ インスティチュート オブ キャンサー メディシン アンド セル バイオロジー 調節性ｔ細胞を同定する方法
WO2009145831A1 (en) * 2008-04-02 2009-12-03 Geisinger Clinic Treatment of the idiopathic nephrotic syndrome spectrum diseases using basiliximab
WO2018159808A1 (ja) * 2017-03-03 2018-09-07 国立研究開発法人国立がん研究センター 抗ｉｌ－７ｒ抗体の抗体薬物コンジュゲートと、がんまたは炎症を処置することに用いるための、抗ｉｌ－７ｒ抗体と細胞傷害剤との抗体薬物コンジュゲートを含む医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
EP0631783A1 (de) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antivirale Kombinationen von 2',3-Di-deoxyribonukleosiden mit 6-benzyl-1-ethoxy-methyl-5-substituierten Uracil-Derivaten
US5567590A (en) * 1994-01-06 1996-10-22 National Jewish Center For Immunology And Respiratory Methods of diagnosing steroid-resistant inflammation due to type I or type II nuclear glucocorticoid receptor binding abnormalities
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
ATE372349T1 (de) * 1998-07-27 2007-09-15 Novartis Pharma Gmbh Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
WO2000025816A1 (en) * 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ES2314067T3 (es) 2009-03-16
BR0208656A (pt) 2004-08-10
AU2002315271B2 (en) 2006-08-03
NZ528411A (en) 2005-04-29
CN1296386C (zh) 2007-01-24
JP2009102367A (ja) 2009-05-14
EP1379557B1 (de) 2008-09-17
CA2443405A1 (en) 2002-10-17
US20040146508A1 (en) 2004-07-29
ATE408629T1 (de) 2008-10-15
EP2058332A1 (de) 2009-05-13
HUP0400986A3 (en) 2012-09-28
US20090274691A1 (en) 2009-11-05
WO2002081508A2 (en) 2002-10-17
PT1379557E (pt) 2008-12-29
SK12212003A3 (sk) 2004-05-04
MXPA03009115A (es) 2004-11-22
HUP0400986A2 (hu) 2004-08-30
PL363029A1 (en) 2004-11-15
KR20030088485A (ko) 2003-11-19
IL158060A0 (en) 2004-03-28
WO2002081508A3 (en) 2003-08-28
KR100975042B1 (ko) 2010-08-11
NO20034453D0 (no) 2003-10-03
EP1379557A2 (de) 2004-01-14
NO20034453L (no) 2003-12-04
CN1527840A (zh) 2004-09-08
KR20080110687A (ko) 2008-12-18
JP2005502593A (ja) 2005-01-27
IL158060A (en) 2009-12-24
CZ20032672A3 (cs) 2003-12-17

Similar Documents

Publication Publication Date Title
FR13C0021I2 (fr) Conjugates d'exendin-4 et leur utilisation medicale
BRPI0417959A (pt) anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável
DE602005026294D1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
DE60239612D1 (de) Monodisperse mischungen und verfahren zur behandlung von diabetes
WO1995027495A3 (en) Treatment of partial growth hormone insensitivity syndrome
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
BR9708656A (pt) Barra suplementar para diabéticos
DE60045681D1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
DE60228945D1 (de) Verwendung von cd25-bindender moleküle für patienten mit steroide-resistenz
TW200630089A (en) Treatment methods
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
NO952336L (no) Insulin analoger
BR9912609A (pt) Métodos de uso de um análogo de somatostatina
ATE460170T1 (de) Therapeutische zusammensetzung enthaltend dentritische zellen und ihre verwendung
PT914148E (pt) Tratamento do sindroma de insensibilidade parcial a hormona de crescimento
DE60227367D1 (de) Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
ATE501760T1 (de) E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
UA31310A (uk) Спосіб лікування хворих на розсіяний склероз
ATE380884T1 (de) Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
UA88604C2 (ru) Применение антитела, которое связывается с альфа-4-интегрином, для лечения демиелинизирующего заболевания

Legal Events

Date Code Title Description
8364 No opposition during term of opposition